CoreAge Rx vs AgelessRx
$93 that nobody can convert into milligrams against $149 that can be — with a footnote on which of those prices is real.
Updated
Disclosure: NAD Picks is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; commissions do not change evidence scores or editorial verdicts. How we make money.
CoreAge Rx
Partner
$93/mo
The cheapest NAD⁺ injection we can verify, at a published $93 a month for either the shot or the nasal spray, with the compounding stated on the product page.
Pick it for: The lower published monthly rate, with no prepayment and needle or spray at one price
AgelessRx
Editorial
$149/mo
Prints the introductory month and the rate that follows it in the same block, and publishes the concentration and vial totals — so the price can actually be checked against a dose.
Pick it for: Concentration, vial totals and a per-injection conversion, if you will prepay a quarter
Our verdict
CoreAge Rx charges $93 a month, published on the product page, with no membership fee, no contract, and the same figure whether you take the injection or the nasal spray. AgelessRx charges $149 and, unusually, says what is in the vial: 200 mg/ml, 500 mg in a 2.5 ml vial, 1,000 mg in a 5 ml one, and a conversion table for each injection volume. That $56 a month is the price of knowing, and it would be a genuine trade — except that the AgelessRx $149 is itself the rate after an introductory month on a quarter billed in full, and the month-to-month plan it advertises carries no published price, so a buyer who will not prepay does not actually know what AgelessRx costs. CoreAge's number has no such condition attached to it, and its nasal spray is included at the same rate where AgelessRx prices its own separately at $125. Buy CoreAge for the lower published monthly rate with nothing committed, and AgelessRx if you would rather pay more and be able to check what you are injecting.
What actually separates them
CoreAge Rx and AgelessRx state different things about published price and states a milligram dose. Everything else they publish, they publish the same way.
AgelessRx costs $56 more than CoreAge Rx — 60% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,116 at CoreAge Rx against $1,788 at AgelessRx — a difference of $672.
| CoreAge Rx | AgelessRx | |
|---|---|---|
| Published price | $93/mo | $149/mo |
| States a milligram dose | No | Yes |
Where they differ on what they tell you
Price is the easy comparison and often the least useful one. These are the places where one of these two answers a question the other leaves open.
- Milligrams
- AgelessRx publishes how much NAD⁺ you get; CoreAge Rx does not, so $93 at CoreAge Rx buys a quantity nobody has told you.
- The advertised price
- CoreAge Rx advertises the rate it goes on charging, while agelessRx leads with quarter paid up front — $79 against $149.
- Routes offered
- AgelessRx also sells a patch, while CoreAge Rx offers only a subcutaneous injection and a nasal spray — which matters if you change your mind about the format later.
- The gap, over a year
- On the injection both sell, CoreAge Rx at $93 against AgelessRx at $149 is 60% — about $672 a year, if you stay on either for twelve months and neither price moves.
What neither of them tells you
A comparison that only reports differences implies everything else is settled. Here it is not.
- Both sell a compounded drug and neither names the pharmacy that compounds it.
- Neither states whether any bloodwork is included, or what it would cost.
Before you choose either
Only one of these two publishes a milligram dose, which makes a straight price comparison impossible: you can tell what each costs, but only one tells you what you get. Ask the other what dose its price buys before you commit, then put both numbers through our cost-per-milligram calculator. A seller that will not answer that question has told you something.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.